UGCG and Parkinson disease: In a previous trial (MOVES-PD, NCT02906020), the glucosylceramide-synthase inhibitor venglustat was investigated in PD patients with a heterozygous GBA-mutation with the aim to lower the substrate for the formation of complex sphingolipids and thereby prevent impairment of lysosomal function and accumulation of toxic αSyn species.